Why Novo Nordisk Stock Jumped a Lucky 7.7% Today

Novo Nordisk may have found a winner in amycretin.Finally, some good news for Novo Nordisk (NVO 7.43%) shareholders!Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical trial results for refinements of its original Ozempic and Wegovy drugs. Twice in the past two months, investors have been disappointed by the numbers -- 22.7% average weight loss over 68 weeks for CagriSema, and 20.7% weight loss for a 72-week regimen of semaglutide ...